SEC Filings
Wave Life Sciences Shareholders Approve 11 Million Additional Shares For Stock Awards
The equity-plan expansion drew 22,936,097 opposing votes; shareholders separately endorsed executive pay.
Wave Life Sciences (WVE) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The equity-plan expansion drew 22,936,097 opposing votes; shareholders separately endorsed executive pay.
SEC Filings
BlackRock holds 13,356,138 Wave shares as of September 30, while Wave posted a $61.9 million third-quarter net loss.
Earnings
CEO Paul Bolno says the three-month look at WVE-007 would show body composition, not weight loss, and an update on timing is coming.
Earnings
After meeting the FDA, Wave says one registrational study of WVE-006 can serve both approval routes, with no separate confirmatory trial.
Earnings
A $12.0 million GSK payment, still owed, drove third-quarter revenue to $13.2 million while cash and equivalents fell to $197.3 million.
Earnings
The biotech says its $431.0 million in cash lasts into the third quarter of 2028, while spending rose from a year earlier.
SEC Filings
The annual proxy puts CEO Paul Bolno's pay at $12,277,916 and shows RA Capital, tied to a director, holding 16.76% of the stock.